WANG, K.,
LIU, H.,
LIU, J.,
WANG, X.,
TENG, L.,
ZHANG, J.,
CHEN, X.,
WANG, N.,
ZHONG, Y.,
HOU, X.,
JIANG, H.,
ZHANG, X.,
ZHAO, S.,
LIU, Y.,
YAO, Y.,
WANG, J.,
QU, Y.,
PENG, F.,
BEYLERLI, O.,
LIAO, X. (2019) that targeting amino acid metabolism such as methionine deprivation/IL1RN related gene
therapy may offer novel
The question of what came first—in this case the diagnosis of prostate cancer or its
therapySharipov, R.A.,
Omarov, M.A.,
Mulyukov, A.R.,
Dybova, A.I.,
Vyaseleva, E.T.,
Kayumova, N.B.,
Saitgalina, A. Sh.,
Ententeev, K.R.,
Iagafarov, I.R.,
Kuserbaev, I.V.,
Gubaeva, E.A. (2023) of gene
therapy methods and attracted the attention of the entire scientific community. This technology
therapy with miRNA to improve the prognosis of patients with this pathology. © 2022 The Authors
Zhiyong, Ji,
Yeping, Ling,
Pingbo, Chen,
Meng, Yuxiao,
Xu, Shancai,
Wu, Pei,
Wang, Chunlei,
Ilyasova, Tatiana,
Sun, Bowen,
Shi, Huaizhang (2023) of recurrent
serious ischemic events despite standard medical
therapy, has been clinically
challenging. A
Beilerli, A.,
Kudriashov, V.,
Sufianov, A.,
Kostin, A.,
Begliarzade, S.,
Ilyasova, T.,
Liang, Ya.,
Mukhamedzyanov, A.,
Beylerli, O. (2023) resistance and promising directions for targeted
therapy. This review presents the results of scientific
in the expression of miRNAs)
and designing their targeted
therapy using specific miRNAs as targets. This article